Colon Cancer Clinical Trial
A Study of Imaging, Blood, and Tissue Samples to Guide Treatment of Colon Cancer and Related Liver Tumors
The purpose of this study is to explore novel ways of diagnosing colon cancer and predicting its propensity to spread to other organs such as the liver.
Patients must be undergoing one of the following procedures as part of their routine care in order to meet the inclusion criteria:
Operation for presumed stage I-IV colon cancer including colectomy, hepatectomy, or abdominal surgery (e.g. insertion of HAIP)
Colectomy for presumed benign or pre-malignant colon tumors (e.g. large nonneoplastic polyps or adenomas)
Open, laparoscopic, or robotic resections
≥18 years old
Extrahepatic CRC metastasis
No preoperative portal venous phase CT scan performed up to two months prior to day of surgery Pathology demonstrating a malignant tumor other than colorectal adenocarcinoma.
Stage IV colon cancer with resectable hepatic disease undergoing hepatectomy with active primary colon tumor still in place (despite chemo-radiation therapy) and no plans for colectomy.
Receipt of experimental therapies for colon cancer (e.g. checkpoint inhibitors or novel targeted agents). Of note, approved targeted agents (such as anti-angiogenic agents, EGFR inhibitors etc) are not an exclusion criterion.
History of non-colonic malignancy w/in 5 years (except non-melanomatous skin cancer)
Colon cancer with microsatellite instability (MSI-high) if known preoperatively
Known hereditary colon cancer syndrome such as familial adenomatous polyposis (FAP) or hereditary nonpolyposis colorectal cancer (HNPCC)
Known liver disease (e.g. non-alcoholic steatohepatitis, cirrhosis, viral or other form of hepatitis, etc)
INR >2 or known clotting factor deficiency
Anticipated need for full anticoagulation during hospitalization
Receipt of medications that increase significantly the risk of bleeding after liver biopsy (at the surgeon"s discretion)
Intraoperative discovery of pathology that precludes the planned surgical resection or liver biopsy, or makes resection futile (such as peritoneal carcinomatosis or other extrahepatic metastatic disease)
Operating surgeon deems research interventions to be more than a minimal risk for the patient
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There are 4 Locations for this study
Basking Ridge New Jersey, 07920, United States More Info
Commack New York, 11725, United States More Info
Harrison New York, 10604, United States More Info
New York New York, 10065, United States More Info
How clear is this clinincal trial information?
Introducing, the Journey Bar
Use this bar to access information about the steps in your cancer journey.